Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Clin. transl. oncol. (Print) ; 24(6): 981-996, junio 2022.
Article in English | IBECS | ID: ibc-203801

ABSTRACT

Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease. HER2 expression is the main biomarker to lead the addition of trastuzumab to first line systemic chemotherapy improving the overall survival in advanced HER2-positivegastric adenocarcinoma. The inevitable development of resistance to trastuzumab remains a great problem inasmuch several treatment strategies that have proven effective in breast cancer failed to show clinical benefit in advanced gastric cancer. In this review, we summarize the available data on the mechanisms underlying primary and secondary resistance toHER2-targeted therapy and current challenges in the treatment of HER2-positive advanced gastric cancer refractory to trastuzumab. Further, we describe the prognostic value of new non-invasive screening techniques, the current development of novel agents such us HER2 antibody–drug conjugates and bispecific antibodies, and the strategies with antitumor activity on going.


Subject(s)
Humans , Adenocarcinoma/drug therapy , Immunoconjugates/therapeutic use , Receptor, ErbB-2/metabolism , Trastuzumab , Stomach Neoplasms/drug therapy , Stomach Neoplasms/metabolism
2.
Clin Transl Oncol ; 24(6): 981-996, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35091998

ABSTRACT

Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease. HER2 expression is the main biomarker to lead the addition of trastuzumab to first line systemic chemotherapy improving the overall survival in advanced HER2-positivegastric adenocarcinoma. The inevitable development of resistance to trastuzumab remains a great problem inasmuch several treatment strategies that have proven effective in breast cancer failed to show clinical benefit in advanced gastric cancer. In this review, we summarize the available data on the mechanisms underlying primary and secondary resistance toHER2-targeted therapy and current challenges in the treatment of HER2-positive advanced gastric cancer refractory to trastuzumab. Further, we describe the prognostic value of new non-invasive screening techniques, the current development of novel agents such us HER2 antibody-drug conjugates and bispecific antibodies, and the strategies with antitumor activity on going.


Subject(s)
Adenocarcinoma , Immunoconjugates , Stomach Neoplasms , Adenocarcinoma/drug therapy , Humans , Immunoconjugates/therapeutic use , Receptor, ErbB-2/metabolism , Stomach Neoplasms/drug therapy , Stomach Neoplasms/metabolism , Trastuzumab/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...